KRYS insider ownership: who sold, why, and what they still hold

What stands out

Dino Rossi sold $13.2M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Feb 19, 2026

A share of stake is shown for 0 of the 6 officers and directors who sold. 11 are left out

Left out: Krish Krishnan, Suma Krishnan, Daniel Janney, Dino Rossi, Kathryn Romano, Laurent Goux, John Thomas, Julian Gangolli, Christopher Mason, Everett Sutherland and Catherine Mazzacco (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Suma Krishnan

President, R&D, Director

Also reported by spouse Krish Krishnan

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$30.0MDisclosed plan

Krish Krishnan

President and CEO, Director

Also reported by spouse Suma Krishnan

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$28.8MDisclosed plan

Daniel Janney

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$19.4MDisclosed plan

Dino Rossi

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$13.2MNo plan disclosed

Kathryn Romano

Chief Accounting Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.6MDisclosed plan

All 6 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 4, 20262 executives sold 50K shares ($18.0M) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Krish Krishnan President and CEO, Director Also reported by spouse Suma Krishnan	25,000	$359.32	n/a	n/a	Sep 4, 2026	Sep 4, 2026
Suma Krishnan President, R&D, Director Also reported by spouse Krish Krishnan	25,000	$359.32	n/a	n/a	Sep 4, 2026	Sep 4, 2026

Common questions

Is the Krystal Biotech, Inc. CEO selling stock?

Yes. Krish Krishnan sold 100K shares ($28.8M) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Krystal Biotech, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 86% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 14% had no disclosed plan. A trading plan schedules sales in advance.

Are any Krystal Biotech, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold6 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Suma Krishnan President, R&D, Director Also reported by spouse Krish Krishnan, President and CEO	$30.0M 106K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Krish Krishnan President and CEO, Director Also reported by spouse Suma Krishnan, President, R&D	$28.8M 100K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Daniel Janney Director	$19.4M 72K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Dino Rossi Director	$13.2M 44K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Kathryn Romano Chief Accounting Officer	$3.6M 13K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
John Thomas EVP, General Counsel	$541K 1.6K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 11 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Krish Krishnan

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Krish Krishnan are complete.

President and CEO, Director

Shares also reported by spouse Suma Krishnan

Same 2.99M shares as Suma Krishnan; counted there

Vesting, gifts, unvested awards and holding lines for Krish Krishnan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Krish Krishnan are complete; balances and unit counts will be added when the check is finished.

−5Kgifted (net of own trusts)

−31Kwithheld by the company for taxes

Some sales match sales reported by Suma Krishnan exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
39,300	$179.25	Feb 28, 2035	$7.4M
45,249	$275.64	Feb 26, 2036	$4.1M

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

Suma Krishnan

President, R&D, Director

Shares also reported by spouse Krish Krishnan

Same 2.99M shares as Krish Krishnan; counted there

Vesting, gifts, unvested awards and holding lines for Suma Krishnan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Suma Krishnan are complete; balances and unit counts will be added when the check is finished.

−5Kgifted (net of own trusts)

−31Kwithheld by the company for taxes

Some sales match sales reported by Krish Krishnan exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,000	$179.25	Feb 28, 2035	$4.7M
18,100	$275.64	Feb 26, 2036	$1.6M

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

Daniel Janney

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Daniel Janney are complete.

Director

n/a

−72K

n/a

Vesting, gifts, unvested awards and holding lines for Daniel Janney

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Daniel Janney are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$183.64	Jun 30, 2034	$915K
5,000	$137.46	Jun 30, 2035	$1.1M
1,187	$340.03	Sep 13, 2036	$31K

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

Dino Rossi

Director

n/a

−44K

n/a

Vesting, gifts, unvested awards and holding lines for Dino Rossi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dino Rossi are complete; balances and unit counts will be added when the check is finished.

−3.7Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$183.64	Jun 30, 2034	$915K
5,000	$137.46	Jun 30, 2035	$1.1M
1,187	$340.03	Sep 13, 2036	$31K

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

Kathryn Romano

Chief Accounting Officer

n/a

−13K

n/a

Vesting, gifts, unvested awards and holding lines for Kathryn Romano

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kathryn Romano are complete; balances and unit counts will be added when the check is finished.

−750gifted (net of own trusts)

−3.5Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
12,500	$63.55	Feb 28, 2032	$3.8M
10,000	$179.25	Feb 28, 2035	$1.9M
13,575	$275.64	Feb 26, 2036	$1.2M

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

Laurent Goux

EVP, Head of International

n/a

Vesting, gifts, unvested awards and holding lines for Laurent Goux

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Laurent Goux are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
9,050	$275.64	Feb 26, 2036	$823K
7,449	$179.25	Feb 27, 2035	$1.4M
2,367	$159.47	Feb 27, 2034	$490K
4,750	$81.91	Feb 27, 2033	$1.4M
2,750	$63.55	Feb 27, 2032	$833K
19,000	$52.21	Sep 29, 2031	$6.0M

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

John Thomas

EVP, General Counsel

n/a

−1.6K

n/a

Vesting, gifts, unvested awards and holding lines for John Thomas

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Thomas are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
9,050	$275.64	Feb 26, 2036	$823K
6,500	$179.25	Feb 27, 2035	$1.2M
2,860	$159.47	Feb 27, 2034	$592K
8,650	$81.91	Feb 27, 2033	$2.5M
1,350	$63.55	Feb 27, 2032	$409K
32,400	$52.21	Sep 29, 2031	$10.2M

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

Julian Gangolli

Director

n/a

Vesting, gifts, unvested awards and holding lines for Julian Gangolli

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Julian Gangolli are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$183.64	Jun 30, 2034	$915K
5,000	$137.46	Jun 30, 2035	$1.1M
1,187	$340.03	Sep 13, 2036	$31K

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

Christopher Mason

Director

n/a

Vesting, gifts, unvested awards and holding lines for Christopher Mason

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Mason are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$183.64	Jun 30, 2034	$915K
5,000	$137.46	Jun 30, 2035	$1.1M
1,187	$340.03	Sep 13, 2036	$31K

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

Everett Sutherland

Director

n/a

Vesting, gifts, unvested awards and holding lines for Everett Sutherland

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Everett Sutherland are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$183.64	Jun 30, 2034	$915K
5,000	$137.46	Jun 30, 2035	$1.1M
1,187	$340.03	Sep 13, 2036	$31K

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

Catherine Mazzacco

Director

n/a

Vesting, gifts, unvested awards and holding lines for Catherine Mazzacco

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Catherine Mazzacco are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$183.64	Jun 30, 2034	$915K
5,000	$137.46	Jun 30, 2035	$1.1M
1,187	$340.03	Sep 13, 2036	$31K

Estimate: options held × ($366.56 − strike price), using the most recent insider trade price on Form 4 (Sep 4, 2026), not a market close.

Holdings and share of stake for Krystal Biotech, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$95.5M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $95.5M across 336,499 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $82.3M · 86%

14%

The lighter segment is sales with no plan disclosed in the filing ($13.2M), including tax-related sales outside a plan.

No plan disclosed · $13.2M

Sales with no 10b5-1 plan and no tax reference in the filing. $13.2M of it is Dino Rossi. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Dino Rossi, Feb 19, 2026

Taxes

64,670 shares ($17.8M) were withheld by the company for taxes, which isn't a market sale.

Charitable gifts · 14K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Suma Krishnan President, R&D, Director	106K	$30.0M	100%	31%	Dec 4, 2025 to Sep 4, 2026
Krish Krishnan President and CEO, Director	100K	$28.8M	100%	30%	Dec 4, 2025 to Sep 4, 2026
Daniel Janney Director	72K	$19.4M	100%	20%	Feb 24, 2026 to Feb 27, 2026
Dino Rossi Director	44K	$13.2M	0%	14%	Feb 19, 2026 to Aug 14, 2026
Kathryn Romano Chief Accounting Officer	13K	$3.6M	100%	4%	Feb 9, 2026 to Mar 2, 2026
John Thomas EVP, General Counsel	1.6K	$541K	100%	0.6%	May 26, 2026 to Jun 25, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$12.3M	$12.3M	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$27.8M	$22.8M	$0	$5.0M
Mar 2026	$13.4M	$13.4M	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$194K	$194K	$0	$0
Jun 2026	$15.8M	$15.8M	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$8.2M	$0	$0	$8.2M
Sep 2026	$18.0M	$18.0M	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 1.6x the 5-year average. 6 insiders sold; the average is 3 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	336K	6	$95.5M
Oct 13, 2025 1 year earlier	151K	3	$24.8M
Oct 13, 2024 2 years earlier	243K	4	$39.3M
Oct 14, 2023 3 years earlier	522K	6	$52.3M
Oct 14, 2022 4 years earlier	150K	2	$11.1M
Oct 14, 2021 5 years earlier	0	0	$0

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty11 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Krystal Biotech, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology185 filings on record, 26 filed in the 12-month period, and how we read them

All 185 Forms 3, 4 and 5 on record for Krystal Biotech, Inc. (SEC CIK 1711279), filed from Sep 19, 2017 to Sep 16, 2026; 26 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (7)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Andrew Orth	Jun 9, 2023	100 shares, last reported balance as of Jun 9, 2023
Jing Marantz	Jan 31, 2022	No balance on record
Jennifer Chien	Feb 4, 2020	No balance on record
Antony Riley	Nov 21, 2019	9,050 shares, last reported balance as of Nov 19, 2019
Douglas Norby	Jun 4, 2018	9,000 shares, last reported balance as of May 9, 2018
Pharma Sun	Sep 25, 2017	No balance on record
Kirti Ganorkar		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Krystal Biotech, Inc. insiders sold $95.5M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Krystal Biotech, Inc. CEO selling stock?

Why are Krystal Biotech, Inc. insiders selling?

Are any Krystal Biotech, Inc. insiders buying?

The evidence

No plan disclosed · $13.2M

Taxes

Charitable gifts · 14K shares

Sales by month